Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brain Metastases
Analysis finds Efaproxyn extends survival in brain metastases originating from breast cancer
January 12th, 2006
Allos Therapeutics, Inc. (ALTH) announced the presentation of new findings from its phase III clinical trial of the investigational radiation sensitizer Efaproxyn (efaproxiral) in patients with brain metastases that show Efaproxyn extends survival in brain metastases originating from breast cancer. Preliminary data from the phase III study, called REACH, were first announced in April 2003. Charles Scott, PhD, CBS Squared, presented the findings in a poster presentation at the 28th Annual San Antonio Breast Cancer Symposium. In abstract No. 4040, titled "Improved Survival, Quality of Life (QOL), and Quality-Adjusted Survival (QAS) in Breast Cancer...
Source: Women's Health Weekly (2006-01-12)
|
